Novo Nordisk’s November 4 results strengthen the evidence for demand for oral Wegovy. As of November 6, 2026, the next question is how much profit survives lower prices and switching from Novo’s existing medicines.
United States (US) third-quarter sales were 4.178 billion Danish kroner (DKK), with approximately 3.6 million prescriptions. Company report, p5. Reuters reported worldwide sales of DKK5.39 billion against consensus of DKK4.62 billion. The underlying forecast submissions and aggregation details were not obtained. That quarterly worldwide beat does not establish outperformance against a 2027 US forecast. November 4 report.
Oral Wegovy contains semaglutide, which activates GLP-1—glucagon-like peptide-1—receptors involved in appetite and food intake. It provides another delivery option for weight management. In OASIS 4, 307 adults with obesity or overweight, without diabetes, received oral semaglutide or placebo alongside lifestyle intervention. Average weight loss at week 64 was 13.6% versus 2.2%; gastrointestinal adverse events occurred in 74.0% versus 42.2%. This was not a comparison with competing medicines. Trial abstract. The label warns about pancreatitis and gallbladder disease and contraindicates use with a personal or family history of medullary thyroid carcinoma. FDA label.
Prescriptions are not people: one patient generates repeat fills. The reviewed US materials do not specify whether 90-day prescriptions are standardised to 30 days. Sales divided by prescriptions gives roughly DKK1,161, but this rough ratio does not establish monthly revenue per patient.
The model instead uses patient-years. For example, 1.8 million people treated for twelve months and 3.6 million treated for six months both produce 1.8 million patient-years. The latter involves more people. To sustain treatment volume when persistence falls, a business must reach more patients.
Prices also measure different things. Current self-pay offers range from $149 to $299 monthly. The planned January 2027 wholesale acquisition cost, or WAC, for the tablets is $675 monthly. Neither equals manufacturer net revenue after rebates and other deductions. NovoCare; company report, p15.
The graphic assumes 1.4–2.2 million patient-years and DKK900–1,200 monthly net revenue per patient. These undisclosed inputs are author assumptions for sensitivity analysis, not a claim of forecasting accuracy. Reported sales are not split by indication, so the financial scope is the US pill business; overlapping treatment populations are not added together.
The central case produces DKK22.68 billion in sales. Its benchmark, DKK16.712 billion, simply multiplies US Q3 sales by four; it is neither actual annual revenue nor company guidance. We assume 30% of any positive difference offsets lost sales of Novo’s other medicines. Below the benchmark, no recovery through other products is assumed. This is not a disclosed switching rate.
With an assumed 40% operating margin, 22% tax rate and fixed share count, central-case net income rises DKK1.303 billion versus that benchmark, or DKK0.29 in earnings per share (EPS). Adding this to an existing company-wide EPS forecast would risk double counting growth already included.
Investing.com reported on October 9 that Citi raised its pill peak-sales estimate to $13 billion while retaining its Neutral stock rating amid margin concerns. The analyst note was not obtained; the peak year and geographic breakdown remain unverified. This cannot serve as a like-for-like 2027 US comparison. No matching company or major-analyst forecast was verified in this search.
Demand is better established. Subsequent sales, persistence, realised net revenue and switching will determine whether that demand translates into additional profit—and whether these assumptions need revising.
This article was prepared with assistance from generative AI.